Analysis of the indications and applicable groups of Canafenib/Encofenib (Betavir)

Canafenib (Encorafenib, trade name Braftovi) is an oral small molecule BRAF inhibitor, mainly used to treat tumor patients carrying BRAF V600 mutations. The drug selectively inhibits BRAF kinase activity and blocks the MAPK signaling pathway, thereby inhibiting tumor cell proliferation and promoting cell apoptosis. Encorafenibis often used in combination with MEK inhibitors (such as Binimetinib) to improve efficacy and reduce the incidence of drug resistance.

In terms of indications, Encorafenib is mainly approved for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Clinical studies have shown that patients treated with MEK inhibitors have significantly longer overall survival (OS) and progression-free survival (PFS). In addition, the drug also shows certain efficacy in patients with BRAF mutated advanced colorectal cancer, especially those who have failed standard chemotherapy regimens.

In terms of applicable population, Encorafenib is mainly targeted at the adult population, especially BRAF V600 mutation-positive patients. Before use, genetic testing is required to confirm the BRAF mutation type to ensure accurate drug targeting. Patients should have good liver and kidney function and a tolerable systemic condition to safely use oral targeted drugs. For patients with serious heart disease, active bleeding or serious infection, the risks of medication should be carefully evaluated under the guidance of a doctor.

In general, canafenib/encofenib is suitable for patients with BRAF V600 mutated advanced or metastatic melanoma and some patients with advanced colorectal cancer. UnitedMEKThe use of inhibitors can significantly improve treatment effects and delay disease progression. Patients should undergo genetic testing and systemic assessment before taking medication, and follow-up regularly during treatment to monitor efficacy and adverse reactions, so as to achieve accurate and safe targeted therapy.

Reference materials:https://www.drugs.com/